Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of RO7034067 in healthy male volunteers
NL-OMON42781Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risdiplam in spinal muscular atrophy (SMA) (14 cohorts), sponsored by Roche. Started Dec 2015; status: active, not recruiting.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON42781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42781.